

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-27 (cancelled).

Claim 28 (currently amended): A method for promoting the take of a graft in a mammal in need thereof, the method comprising:

- a) taking the graft from one or more of the group consisting of a suitable donor, a cell culture and a suitable tissue,
- b) administering to ~~said graft a non-mineralized tissue recipient bed or lesion a~~ prophylactically effective amount of an active enamel substance, and
- c) placing the graft; ~~on said pre-treated with the active enamel substance, on a non-~~ mineralized tissue recipient bed or lesion.

Claim 29 (previously presented): A method according to claim 28, wherein the active enamel substance is applied in an amount of total protein per cm of graft bed area corresponding to from about 0.01 mg/cm<sup>2</sup> to about 20 mg/cm<sup>2</sup>, such as from about 0.1 mg/cm<sup>2</sup> to about 15 mg/cm<sup>2</sup>.

Claim 30 (currently amended): A method according to claim 28, wherein the active enamel substance is applied on the site of the recipient bed or lesion ~~graft~~ before application of the graft described in step c).

Claim 31 (currently amended): A method according to claim ~~28~~30, wherein the active enamel substance is applied for a period of up to 72 hours before the application of the graft.

Claim 32 (previously presented): A method according to claim 28 wherein the graft is a skin graft or mucosal graft.

Claim 33 (previously presented): A method according to claim 28 wherein the graft is an autogenous skin graft.

Claim 34 (previously presented): A method according to claim 28 wherein the graft is a full-thickness, split-thickness, composite, seed or mesh graft.

Claim 35 (previously presented): A method according to claim 28 wherein the graft comprises epidermal cells.

Claims 36-40 (cancelled).

Claim 41 (previously amended): A method according to claim 28 wherein the active enamel substance is enamel matrix, enamel matrix derivatives, enamel matrix proteins, or mixtures thereof.

Claim 42 (previously amended): A method according to claim 28 wherein the active enamel substance is selected from the group consisting of enamelines, amelogenins, non-amelogenins, proline-rich amelogenins, amelins and tuftelins, and derivatives of said substances.

Claim 43 (previously presented): A method according to claim 28 wherein the active enamel substance has a molecular weight of up to about 120 kDa as determined by SDS Page electrophoresis.

Claim 44 (previously presented): A method according to claim 28 wherein the active enamel substance has a molecular weight of up to about 100 kDa as determined by SDS Page electrophoresis.

Claim 45 (previously presented): A method according to claim 28 wherein the active enamel substance has a molecular weight of up to about 60 kDa as determined by SDS Page electrophoresis.

Claim 46 (previously presented): A method according to claim 28 wherein the preparation of an active enamel substance contains a mixture of active enamel substances with different molecular weights.

Claim 47 (previously amended): A method according to claim 28 wherein the preparation of an active enamel substance comprises at least one substance selected from the group consisting of amelogenins, proline-rich non-amelogenins, tuftelins, tuft proteins, serum proteins, salivary proteins, amelin, ameloblastin, sheathlin, and derivatives thereof.

Claim 48 (previously presented): A method according to claim 28 wherein the active enamel substance has a molecular weight of between about 5,000 and about 25,000.

Claim 49 (previously presented): A method according to claim 28 wherein the major part of the active enamel substance has a molecular weight of about 20kDa.

Claim 50 (previously presented): A method according to claim 28 wherein at least a part of the active enamel substance is in the form of aggregates or after application in vivo is capable of forming aggregates.

Claim 51 (previously presented): A method according to claim 28 wherein the aggregates have a particle size of from about 20 nm to about 1  $\mu$ m.

Claim 52 (previously presented): A method according to claim 28 wherein the protein content of the active enamel substance in the preparation is in a range of from about 0.05% w/w to 100%

w/w.

Claim 53 (previously presented): A method according to claim 28 wherein the protein content of the active enamel substance in the preparation is in a range of from about 30-90% w/w.

Claim 54 (currently amended): A method according to claim 28 wherein a pharmaceutical or cosmetic composition comprising an active enamel substance and a pharmaceutically acceptable excipient is ~~in step b) administered to a mammalian recipient bed or lesion~~ ~~the mammal~~.

Claim 55 (previously amended): A method according to claim 54 wherein the pharmaceutically or cosmetically acceptable excipient is propylene glycol alginate.

Claims 56-64 (cancelled).

Claim 65 (new): A method according to claim 28, wherein the active enamel substance is applied as a thin layer between the graft and recipient bed after application of the graft as described in step c).